OCTAPHARMA AG
History
| Year | Detail |
|---|---|
| 1983 | Wolfgang Marguerite established Octapharma to treat people with hemophilia and allow access to better products. |
| 1985 | The company introduced Octavi, a virally inactivated FVIII concentrate medicine developed using the S/D method available to hemophilia patients. |
| 1999 | Octapharma AG acquired Aventis's production site based in Lingolsheim, France, to maximize the production capacity at the site in Mexico. |
| 2002 | Octapharma AG acquired Biovitrum's third manufacturing site to increase its products portfolio to increase product portfolio in Stockholm, Sweden. |
| 2006 | The company has acquired five plasma donation centers from Deutsche Gesellschaft für Human plasma. |
| 2007 | Octapharma Plasma Inc. was established to operate its plasma donation centers in the U.S. |
| 2012 | Octapharma AG opened the Institute for Recombinant Protein Research & Development to further invest in advanced therapies in Heidelberg, Germany. |
| 2016 | Panzyga received regulatory approvals in Canada and the EU for primary immunodeficiency syndromes and immune thrombocytopenia. |
| 2023 | European authorities have approved the lyophilized presentation of Octapharma's pooled S/D treated human plasma, octaplasLG, used for transfusion in a pre-hospital setting. |
BCC Research Beacon 